Syndax Q1 2022 net loss $37.2M; cash $397.9M; clinical milestones on track for 2023

Syndax Pharmaceuticals Inc

2023-Q1 EPS reported -$0.63

Net loss $37.2M ($0.63/sh) vs $27.7M ($0.54) in Q1 2021; R&D spend $30.0M vs $21.9M.
Cash, cash equivalents and short-term investments $397.9M; 59M shares and equivalents outstanding.
FY2022 guidance: R&D $130-140M, total opex $160-170M; Q2 opex $38-42M.
Revumenib: AUGMENT-101 enrollment completion expected later 2022; topline data 1H23; combination trials underway.
Axatilimab: FDA Fast Track for cGVHD; AGAVE-201 topline data 1H23; potential BLA filing 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.